Skip to content
Stock screener

AYTU Aytu Biopharma, Inc stock chart & analysis

Conviction 40HealthcareScan · Mon, Nov 16, 2026

Aytu Biopharma, Inc (AYTU) closed at $1.78 on Nov 16, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 22, -41.9% from its 52-week high, -31.5% year to date. Sector: Healthcare · Pharmaceutical Preparations.

AYTU$1.78
ResistanceSupportVol 14
Loading chart…
Aytu Biopharma, IncPharmaceutical Preparationswww.aytubio.com ↗
Price1.78
Change—
Gap-1.12%
Rel volume—
Avg volume26.06K
Avg $ vol49.06K
SMA 201.90
SMA 502.01
SMA 2002.28
Price vs 50-11.57%
Price vs 200-21.78%
MA stackbearish
50/200 cross—
Supertrenddown · 2.13
RSI (14)33
MACD hist-0.01
MACD crossbear · 6d
Stoch %K / %D11 / 16
ADX (14)20
+DI / −DI10 / 18
RSI divergence—
MACD divergence—
ATR %5.99%
ADR %5.45%
52w high3.07
52w low1.75
From 52w high-41.92%
Above 52w low+1.71%
New 52w highNo
SqueezeOff
Bollinger width15.59%
%B0.11
Donchian pos8.11%
Donchian high2.12
Donchian low1.75
AVWAP (52w high)2.41
vs AVWAP high-26.20%
AVWAP (52w low)1.83
vs AVWAP low-2.49%
OBV trendDown
Chaikin MF (20)-0.41
Today vs 20d—
Avg vol (14d)30.28K
Avg vol (20d)26.06K
Avg $ vol (20d)49.06K
Market cap19.35M
RS Rating22 / 99
RS 3m (vs SPY)-22.21%
RS 6m (vs SPY)-20.78%
RS line new highNo
Trend template0/8
Technical rank26.0
1 week-2.73%
1 month-11.44%
3 months-24.58%
6 months-18.72%
1 year-13.59%
YTD-31.54%
P/E-1.36
P/B0.61
P/S0.34
P/FCF5.95
EPS-1.16
Div yield—
ROE-45.15%
ROA-14.37%
Debt/Eq0.33
Current1.07
EV/EBITDA-0.99
Gross margin63.95%
Net margin-24.76%
Rev growth-13.27%
EPS growth-5.09%
Price target—
Target upside—
Analyst rating—
Institutional72.81%
Ent. value4.36M
Revenue14.84M
Net income-3.88M
Gross profit9.44M
Free cash flow3.25M
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out10.73M
Employees83
ListedFri, Feb 15, 2008
Free float7.2M
Float %67.1%
Short interest—
Days to cover—
Short volume54.2%
Squeeze score—
Next earningsNov 16 · after (0d)
EPS forecast−$0.10 · 1 est
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction40 / 100
Pattern quality—
Tech rank26.0 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance2.25
Support1.75
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

AYTU technical analysis

Trend

AYTU is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 11.6% below the 50-day ($2.01) and 21.8% below the 200-day ($2.28). ADX(14) at 20 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 33, in the bearish half of its range. MACD crossed below its signal line 6 sessions ago. Its RS Rating of 22 puts its weighted 12-month performance ahead of about 22% of the US market.

Volume and volatility

It trades about $49,057 a day on average. ATR(14) is $0.1065, 6.0% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.41) shows distribution.

Key levels

The chart pattern's support is $1.75 and its resistance $2.25. The 52-week range is $1.75 to $3.07; price is 41.9% below the high and 1.7% above the low. The VWAP anchored at the 52-week high is $2.41, above price.

Performance

AYTU returned -2.7% (1 week), -11.4% (1 month), -24.6% (3 months), -18.7% (6 months), -13.6% (1 year), -31.5% (year to date).

About Aytu Biopharma, Inc

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Pharmaceutical Preparations · Listed 2008 · 83 employees

SEC filings

EDGAR filings in AYTU · 6 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.